The Bewildering Antitubercular Action of Pyrazinamide

Elise A. Lamont, Nicholas A. Dillon, Anthony D. Baughn

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


SUMMARYPyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease relapse rates, PZA is considered an irreplaceable component of standard first-line short-course therapy for drug-susceptible TB and second-line treatment regimens for multidrug-resistant TB. Despite over 60 years of research on PZA and its crucial role in current and future TB treatment regimens, the mode of action of this unique drug remains unclear. Defining the mode of action for PZA will open new avenues for rational design of novel therapeutic approaches for the treatment of TB. In this review, we discuss the four prevailing models for PZA action, recent developments in modulation of PZA susceptibility and resistance, and outlooks for future research and drug development.

Original languageEnglish (US)
JournalMicrobiology and molecular biology reviews : MMBR
Issue number2
StatePublished - May 20 2020


  • antimicrobial activity
  • coenzyme A
  • drug resistance
  • drug resistance mechanisms
  • drug susceptibility
  • mode of action
  • pyrazinamide
  • tuberculosis

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint Dive into the research topics of 'The Bewildering Antitubercular Action of Pyrazinamide'. Together they form a unique fingerprint.

Cite this